Biotechnology

Invitation to FluoGuide A/S Live Webcast on 25 August 2026

August 12, 2026 5:08 AM

FluoGuide A/S (STO:FLUO) will publish its interim report for Q2 2026 on Tuesday, 25 August 2026. Later that day, CEO Morten Albrechtsen and CFO Ole Larsen will present the company's operational and financial results for Q2 2026 in a live webcast. The webcast is hosted and moderated by Cecilia Hallström, BioStock. The presentation will be followed by a live Q&A session, where questions can be asked during the event or submitted in advance by...

Read more

eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026

August 11, 2026 4:10 PM

CEO of eXoZymes, Michael Heltzen, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period. Investors can pre-register for the webinar HERE. On the day of the event, the live webinar can also be accessed through eXoZymes' investor relations website at https://exozymes.com/investor. About eXoZymes Founded...

Read more

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

August 11, 2026 8:52 AM

OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from its Chief Executive Officer to shareholders. Dear Shareholders, Today marks five business days before August 18, the practical deadline by which the Nasdaq is expected to communicate its determination regarding OSRH's continued listing if our stock price has not regained the minimum bid price requirement of $1.00 per share as of the market close. As CEO of OSRH, I want to...

Read more

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout

August 11, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing treatments for Alzheimer's disease, today announced that it is strengthening its regulatory, biostatistical, artificial intelligence ("AI")-enabled data science, and strategic pharmaceutical development capabilities as IGC-AD1, the Company's lead Alzheimer's drug candidate, advances toward expected Phase 2 topline results in the...

Read more

Remedium Bio Announces Initial Close of Series A Financing to Advance Durable Protein Therapeutics Platform Toward First-in-human Clinical Development

August 10, 2026 9:00 AM

Remedium Bio, Inc. ("Remedium"), a biotechnology company developing durable protein therapeutics, today announced the initial closing of its planned $10 million Series A financing. The round is led by Lifespan Vision Ventures, with participation from Eli Lilly and Company ("Lilly") and HKX Capital. In connection with the financing, Harry Robb of Lifespan Vision Ventures has joined Remedium's Board of Directors. Remedium's proprietary platforms...

Read more

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

August 7, 2026 3:00 PM

OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today issued a clarification regarding its press release dated July 31, 2026 concerning the Nasdaq Stock Market ("Nasdaq") and the Company's Shareholder Loyalty CVR Program. The Company is clarifying that the statement in the prior release, "The communication affirms that our loyalty program is additive and gives shareholders clarity," should not be interpreted as indicating that...

Read more

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

August 7, 2026 8:35 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update on continued execution of its long-term strategy to advance its proprietary DNase platform through scientific collaboration and translational...

Read more

BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer

August 7, 2026 5:20 AM

BioInvent International AB ("BioInvent") (NASDAQ Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of ovarian cancer in combination with pembrolizumab. "Receiving FDA Fast Track Designation for BI-1808 in ovarian cancer is an important milestone...

Read more

Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada

August 6, 2026 4:15 PM

Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC PINK:BMNDF), a clinical-stage biopharmaceutical company focused on transforming breakthroughs in neuroscience and biomedical research into novel pharmaceutical drugs, is pleased to announce that it has received approval to list its common shares (the "Common Shares") on the Canadian Securities Exchange (the "CSE"), and the Common Shares will commence trading on the CSE at market open...

Read more

Microbix Schedules Release of Results for Q3 Fiscal 2026

August 6, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF), (Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its third quarter of fiscal 2026 ended June 30, 2026 ("Q3 2026") prior to the start of trading on August 13, 2026. At 10:00 AM ET that day, Microbix intends to hold a webinar discussion of Q3 2026 results...

Read more

Biovica Signs Laboratory Services Agreement with Leading U.S. Cancer Center

August 6, 2026 3:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a company specializing in blood-based cancer monitoring, today announced that it has entered into a laboratory services agreement with one of the leading cancer centers in the United States, designated by the National Cancer Institute as a Comprehensive Cancer Center. The agreement establishes the framework for the cancer center to access DiviTum® TKa testing services through...

Read more

Lobe Sciences Announces Results of Annual General and Special Meeting of Shareholders

August 5, 2026 8:00 AM

Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, today announced the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held on July 30, 2026. A total of 152,807,032 common shares were represented at the Meeting, representing approximately 49.6% of the Company's...

Read more

Faron Pharmaceuticals LTD: Holding(s) in Company

August 5, 2026 7:15 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals OY 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer...

Read more

Faron Pharmaceuticals LTD: Holding(s) in Company

August 4, 2026 9:15 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) Faron Pharmaceuticals Ltd | Company announcement | August 04, 2026 at 16:00:00 EEST TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals Ltd 1b....

Read more

Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments

August 4, 2026 8:46 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today highlighted the publication of a landmark, peer-reviewed health economic analysis in the Journal of Vascular Surgery: Venous and Lymphatic Disorders demonstrating the potential clinical and economic benefits of venous valve replacement therapy for patients with severe deep venous reflux. The publication titled, "Cost-effectiveness of a prosthetic venous valve...

Read more

New Publication Strengthens the Case for DiviTum TKa in Early Treatment Assessment

August 4, 2026 3:15 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a company specializing in blood-based cancer monitoring, today announced that new results involving DiviTum® TKa have been published in the peer-reviewed journal Clinical Cancer Research. The study evaluated a new treatment combination for patients with advanced breast cancer whose disease had progressed after previous CDK4/6 inhibitor treatment. The combination included...

Read more

Pinnacle Food Group Limited Appoints Mr. Martin Ngai Lam Cheung as Independent Director

August 3, 2026 4:35 PM

Pinnacle Food Group Limited (NASDAQ:PFAI) (the "Company"), today announced the appointment of Mr. Martin Ngai Lam Cheung as an independent director of the Company, effective August 1, 2026. Mr. Cheung, 57, has extensive public company board, audit committee, corporate finance, accounting, reporting and compliance experience. He currently serves as an independent non-executive director and audit committee chair of China Development Bank...

Read more

ClearPoint Neuro Reports Second Quarter 2026 Results

August 3, 2026 4:05 PM

ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its second quarter ended June 30, 2026. Second Quarter 2026 Highlights Reported second quarter revenue of $10.9 million, representing 18% overall growth, including the recently acquired IRRAflow Portfolio; Biologics and Drug Delivery Revenue...

Read more

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform

August 3, 2026 9:02 AM

OSR Health, Inc. (NASDAQ:OSRH) today announced that its subsidiary Vaximm AG has completed the analysis of results from two clinical studies evaluating VXM01, an oral DNA vaccine targeting the vascular endothelial growth factor receptor 2 (VEGFR-2), in patients with recurrent glioblastoma. Prof. Wolfgang Wick, M.D., Chairman of the Neurology Clinic of Heidelberg University and the principal investigator of these trials, commented that "these...

Read more

ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel

July 31, 2026 4:05 PM

ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulated its partner Aspen Neuroscience, Inc. on receiving Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for sasineprocel (ANPD001), Aspen's investigational autologous dopaminergic neuron cell replacement therapy...

Read more